Loading...
Recent reports on drug development for patients with castration-resistant prostate cancer (CRPC) have appropriately focused on new androgen receptor–targeted agents, such as abiraterone (JW Oncol Hematol Dec 18 2012) and enzalutamide (JW Oncol Hematol Sep 11 2012), as well on as other agents with diverse targets and mechanisms of action, such as sipuleucel-T (JW Oncol Hematol Jul 28 2010), cabazitaxel (JW Oncol Hematol Oct 26 2010), and radium 223. Recently, another multitargeted agent, the oral tyrosine kinase inhibitor cabozantinib, demonstrated activity against vascular endothelial growth factor receptor 2 and mesenchymal-epithelial transition factor (MET), both of which are overexpressed in CRPC. In an early report of an international, …